Formulations and methods for treating rhinosinusitis
View Patent ↗The invention involves methods and formulations for treating or preventing rhinosinusitis, including fungus-induced rhinosinusitis in mammals. In one embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory agent having a specific particle size distribution profile. The formulation may also comprise an antifungal agent, antibiotic or antiviral agent.
1. A formulation for the treatment of fungus-induced rhinosinusitis in a mammal, said formulation comprising an aqueous suspension comprising:
(a) about 0.05% by weight of suspended solid steroidal anti-inflammatory particles, wherein the steroidal anti-inflammatory is fluticasone or a pharmaceutically acceptable salt, ester, enol ether, enol ester, acid, or base thereof, said suspended solid steroidal anti-inflammatory having the following particle size distribution profile:
i. about 10% of the solid steroidal anti-inflammatory particles have a particle size of less than 0.4 microns;
ii. about 25% of the solid steroidal anti-inflammatory particles have a particle size of less than 0.8 microns;
iii. about 50% of the solid steroidal anti-inflammatory particles have a particle size of less than 1.5 microns;
iv. about 75% of the solid steroidal anti-inflammatory particles have a particle size of less than 3.0 microns; and
v. about 90% of the solid steroidal anti-inflammatory particles have a particle size of less than 5.3 microns; and
(b) an antifungal agent;
wherein the formulation is sterile and has a relatively long period of stability such that after storage for 12 months at a temperature between 15 to 30° C., greater than 90% of the fluticasone originally present in the formulation still remains in the formulation.
2. The formulation of claim 1 , wherein the antifungal agent comprises from 0.5 to 150 mg of amphotericin β.
3. The formulation of claim 1 , wherein said formulation comprises about 7.5 to about 15 mg of amphotericin β.
4. The formulation of claim 1 , wherein said formulation comprises about 10 mg of amphotericin β.
5. The formulation of claim 1 , comprising about 50 mcg of said steroidal anti-inflammatory.
6. The formulation of claim 1 , comprising about 75 to about 300 mcg of said steroidal anti-inflammatory.
7. The formulation of claim 1 , wherein the formulation is sterile.
8. The formulation of claim 1 , wherein the formulation further comprises a preservative.
9. The formulation of claim 8 , wherein the preservative is benzalkonium chloride.
10. The formulation of claim 1 , wherein the formulation is in a metered-dose spray pump bottle.
11. The formulation of claim 1 , further comprising about 0.01% to about 90% by weight on a dried weight basis of one or more of the following compounds:
(a) microcrystalline cellulose;
(b) carboxymethyl cellulose sodium;
(c) dextrose;
(d) benzalkonium chloride;
(e) polysorbate 80; and
(g) phenylethyl alcohol.
12. The formulation of claim 1 , further comprising an antibiotic.
13. The formulation of claim 12 , wherein the antibiotic is one or more selected from the group consisting of amikacin, azithromycin, aztreonan, cefazolin, cefepine, cefonicid, cefaperazone, cefotaxime, cefotetan, cefoxitin, ceftazidime, ceftizoxime, ceftriaxone, cefuroxime, cephapirin, ciprofloxacin, clindamycin, doxycycline, erythromycin lactobionate, gentamicin, kanamycin, linezolid, mezlocillin, mupirocin, nafcillin, netilmicin, neomycin, oxacillin, paromomycin, piperacillin, streptomycin, ticarcillin, tobramycin, and vancomycin.
14. The formulation of claim 1 further comprising at least one complexing agent wherein the at least one complexing agent is sodium edetate.
15. A formulation for the treatment of fungus-induced rhinosinusitis, said formulation comprising an aqueous suspension comprising:
(a) amphotericin β;
(b) about 0.045% to about 0.05% by weight of suspended solid steroidal anti-inflammatory fluticasone propionate particles having the following particle size distribution profile:
ii. about 10% of the solid steroidal anti-inflammatory particles have a particle size of less than 0.40 microns;
iii. about 25% of the solid steroidal anti-inflammatory particles have a particle size of less than 0.80 microns;
iv. about 50% of the solid steroidal anti-inflammatory particles have a particle size of less than 1.5 microns;
v. about 75% of the solid steroidal anti-inflammatory particles have a particle size of less than 3.0 microns;
vi. about 90% of the solid steroid particles have a particle size of less than 5.3 microns; and,
(c) at least one complexing agent selected from the group consisting of ethylenediaminetertraacetic acid, citric acid, nitrilotriacetic acid, salts thereof, and sodium edetate;
wherein said formulation comprises a pH from about 3 to about 7 and is suitable for administration to the nasal-paranasal mucosa, and wherein the formulation is sterile and has a relatively long period of stability such that after storage for 12 months at a temperature between 15 to 30° C., greater than 90% of the fluticasone originally present in the formulation still remains in the formulation.
16. The formulation of claim 15 , wherein the at least one complexing agent is sodium edetate.
17. A formulation for the treatment of fungus-induced rhinosinusitis, said formulation comprising an aqueous suspension comprising:
(a) a therapeutic amount of an antiviral agent selected from the group consisting of Acyclovir, Famciclovir, Valacyclovir, edoxudine, ganciclovir, foscarnet, cidofovir (vistide), Vitrasert and Formivirsen
(b) about 7.5 to about 15 mg of amphotericin 13;
(c) about 10 to about 100 mg of doxycycline
(d) about 0.045% to about 0.05% by weight of suspended solid steroidal anti-inflammatory fluticasone propionate particles having the following particle size distribution profile:
ii. about 10% of the solid steroidal anti-inflammatory particles have a particle size of less than 0.4 microns;
iii. about 25% of the solid steroidal anti-inflammatory particles have a particle size of less than 0.8 microns;
iv. about 50% of the solid steroidal anti-inflammatory particles have a particle size of less than 1.5 microns;
v. about 75% of the solid steroidal anti-inflammatory particles have a particle size of less than 3.0 microns;
vi. about 90% of the solid steroid particles have a particle size of less than 5.3 microns; and,
(e) at least one complexing agent selected from the group consisting of ethylenediaminetertraacetic acid, citric acid, nitrilotriacetic acid, salts thereof, and sodium edetate;
wherein said formulation comprises a pH from about 3 to about 7 and is suitable for administration to the nasal-paranasal mucosa and wherein the formulation is sterile and has a relatively long period of stability such that after storage for 12 months at a temperature between 15 to 30° C., greater than 90% of the fluticasone originally present in the formulation still remains in the formulation.
18. The formulation of claim 17 , wherein the antiviral agent is edoxudine.